27 Sep 21 | Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD...
Pearce IP BioBlast®: w/e 01 October 2021
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Taking a position on patent infringement – position statements where multiple products accused
Surefoot IP Holdings Pty Ltd v All Footings Solutions Pty Ltd [2021] FCA 1181
Date: 30 September 2021Court: Federal Court of AustraliaJudge: Rofe J Background The patentee (Surefoot) alleged that...
Pearce IP BioBlast®: w/e 24 September 2021
18 Sep 21 | Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a...
Wrinkle for supplier of Botox ‘alternative’ as Court finds trade mark infringed, Australian Consumer Law breached
The Full Federal Court has held a supplier of cosmetic products (Self Care) liable to Allergan for infringing its...
Economy of court procedures primary factor in refusal to consider summary judgment application
Deco Australia Pty Ltd v Aliwood Pty Ltd [2021] FCA 1159
Date: 22 September 2021Court: Federal Court of AustraliaJudge: Perram J Background Deco Australia Pty Ltd (Deco)...
New .au domain names coming to Australia
New .au domain names will be available in Australia from 24 March 2022. From this date, individuals, businesses and...
Pearce IP BioBlast®: w/e 17 September 2021
13 Sep 21 | Samsung Bioepis reported on a five-year follow-up study comparing ONTRUZANT® (trastuzumab biosimilar) with...
Pearce IP BioBlast®: w/e 10 September 2021
02 Sep 21 | US | Amgen and Hospira appear ready to settle the ongoing dispute relating to Neupogen® (filgrastim). The...
Federal Court Confirms Higher Bar for Sufficiency and Support in Australian Patent Law
Nalco Patent Application Claiming Inhibitors of Silica Deposits Invalid: a Question of Scale
A recent decision of Justice Burley in the Federal Court of Australia confirms that the bar for sufficiency and...
Pearce IP BioBlast®: w/e 03 September 2021
26 Aug 21 | US | Two former executives of JHL Biotech plead guilty to conspiracy to steal trade secrets and commit...
Pearce IP BioBlast®: w/e 27 August 2021
24 Aug 21 | UCB announced that it has gained EU marketing approval for Bimzelx® (bimekizumab), an IL-17A and IL-17F...
Pearce IP BioBlast®: w/e 20 August 2021
17 Aug 21 | US | The USPTO Patent Trial and Appeal Board (PTAB) will review Amgen’s US 8,273,707 Patent (related to...
Consider the Bar Raised for Sufficiency and Support: Nalco Patent Application Claiming Inhibitors of Silica Deposits Invalid
Cytec Industries Inc. v Nalco Company [2021] FCA 970
Date: 19 August 2021Court: Federal Court of AustraliaJudge: Burley J Background The ‘Bayer process’ has been used for...
PTEs in Australia – more hard lessons for patentees from the Federal Court
The Australian Federal Court has confirmed in Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947 that, when...
Pearce IP BioBlast®: w/e 13 August 2021
05 Aug 21 | A new study reported that the safety profiles and pharmacokinetic parameters of Amgen’s ABP980 (biosimilar...
PTEs in Australia – hard lessons for patentees from the Federal Court
Merck Sharp & Dohme Corp. v Sandoz Pty Ltd [2021] FCA 947
Date: 12 August 2021Court: Federal Court of AustraliaJudge: Jagot J Background Under Australian law, a patent term...